Mechoub Donia, Meguenni Nacima, Titouche Yacine, Elandoulsi Ramzi Boubaker, Dhaouadi Sana
Laboratory of Analytical Biochemistry and Biotechnology (LABAB), Faculty of Biological Sciences and Agricultural Sciences, University Mouloud Mammeri, Tizi Ouzou, Algeria.
ISBST, BVBGR-LR11ES31, Biotechpole Sidi Thabet, University of Manouba, 2020, Ariana, Tunisia.
World J Microbiol Biotechnol. 2025 Jun 25;41(7):214. doi: 10.1007/s11274-025-04389-5.
Enterococci, a subset of lactic acid bacteria, are ubiquitous in a variety of ecosystems, including the gastrointestinal tracts of mammalian and avian species. Due to their extreme adaptability, enterococci thrive in exceptionally unfavorable conditions characterized by high salinity levels, exposure to bile salts, a wide range of pH variations and high-temperature thresholds. Investigation into enterococcal strains as potential probiotics has encompassed the fields of human health, animal husbandry and companion animal welfare. In the context of human applications, the objectives are related to increasing immune responses, reducing cholesterol levels and providing anti-inflammatory and antioxidant attributes. Similarly, the livestock sector has recognized the potential of enterococci to stimulate growth, inhibit pathogen proliferation and amplify immune reactivity. Pet health interventions using enterococci aim to balance the microbiota, boost immune function and improve the animal's general well-being. The mechanisms of probiotic effects mediated by enterococci are manifold, including the production of enterocins, improvement of cholesterol levels, immunomodulation, antioxidant activities, attenuation of inflammatory cascades and the support of liver functions. While enterococcal probiotics hold great promises for optimizing human and animal health, safety considerations must be taken into account. Given the pathogenic character of enterococci and their capacity to carry antibiotic resistance determinants, rigorous evaluation of safety profiles is an imperative prelude to their judicious use as probiotics.
肠球菌是乳酸菌的一个子集，广泛存在于各种生态系统中，包括哺乳动物和鸟类的胃肠道。由于其极强的适应性，肠球菌能在盐度高、接触胆盐、pH值变化范围广和温度阈值高的极端不利条件下茁壮成长。对作为潜在益生菌的肠球菌菌株的研究涵盖了人类健康、畜牧业和伴侣动物福利等领域。在人类应用方面，目标包括增强免疫反应、降低胆固醇水平以及提供抗炎和抗氧化特性。同样，畜牧业也认识到肠球菌具有促进生长、抑制病原体增殖和增强免疫反应的潜力。使用肠球菌进行宠物健康干预旨在平衡微生物群、增强免疫功能并改善动物的总体健康状况。肠球菌介导的益生菌作用机制是多方面的，包括产生肠球菌素、改善胆固醇水平、免疫调节、抗氧化活性、减轻炎症级联反应以及支持肝脏功能。虽然肠球菌益生菌在优化人类和动物健康方面前景广阔，但必须考虑安全因素。鉴于肠球菌的致病性及其携带抗生素耐药性决定因素的能力，在将其明智地用作益生菌之前，对安全性进行严格评估是必不可少的前奏。
